Jennison Associates’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Jennison Associates’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,613,159	Closed	-$7.03M	–	688
2016 Q1	$7.03M	Buy	2,613,159 +15,291	+0.6%	+$42.9K	0.01%	476
2015 Q4	$8.03M	Buy	2,597,868 +3,912	+0.2%	+$17.6K	0.01%	495
2015 Q3	$11.5M	Sell	2,593,956 -36,986	-1%	-$217K	0.01%	499
2015 Q2	$15M	Buy	2,630,942 +15,948	+0.6%	+$109K	0.01%	488
2015 Q1	$23.4M	Buy	+2,614,994	New	+$21M	0.02%	427
2014 Q4	–	Sell	-12,436	Closed	-$89K	–	803
2014 Q3	$89K	Buy	+12,436	New	+$107K	﹤0.01%	717

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jennison Associates's EPRS Position: Q2 2016 in Review

Jennison Associates sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 2,613,159 shares — an estimated $7.03M sold.

Jennison Associates first reported a position in EPRS in Q3 2014 and held it in 6 quarters. The position peaked at $23.4M in Q1 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

Jennison Associates reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Jennison Associates sold 2,613,159 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $7.03M.
Jennison Associates first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 6 quarters.
Jennison Associates's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $23.4M in Q1 2015.
32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Jennison Associates's 13F filing for Q2 2016, filed 3 Aug 2016.